Tuesday, May 27, 2014
AUGUSTA, Ga. (WRDW) -- An initiative making it possible to treat children with epilepsy with oil extracted from marijuana is moving forward.
The State of Georgia, GW Pharmaceuticals, and Georgia Regents University-Augusta announced they have entered into a Memorandum of Understanding to study GW’s investigational cannabidiol (CBD) product Epidiolex® in the treatment of children with medication-resistant epilepsies, according to a release.
"I have learned the stories of brave Georgia families desperately seeking treatment for their children’s debilitating condition," Deal said in a release. "As governor, it is my responsibility to address the needs of and protect our state's most vulnerable citizens, especially when they are suffering. I’m grateful to Georgia Regents University and GW Pharmaceuticals for their leadership on this venture, and I’m confident that this public-partnership will deliver relief and improve quality of life for these children and their families."
“As the state’s public academic medical center, our primary missions are patient care, education, and research,” said GRU President Dr. Ricardo Azziz. “We have a responsibility to bring the medicine of tomorrow to patient care today. We are excited to partner with GW Pharmaceuticals to study investigational cannabidiol and potentially change the lives of children with medication-resistant epilepsies.”